| Patient | Martin Luther |
|---|---|
| Date of birth | 1982-11-19 |
| Identifiers | MRN HR-RE004-SYN; SSN (made up) 000-04-3892 |
| Document date | 2026-08-11 |
| Author | Ottilie Brandt-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of vertigo attacks and low mood, seen the same day in otology. [S]
Professor Luther returns two weeks after his first visit, on the day of his consultation with Dr. Okafor-Lindqvist. He has kept the attack diary. He had one attack six days ago that began with roaring and fullness in the left ear, then spinning for about three hours with nausea; he lay down, took one meclizine and slept, and the roaring settled back to its usual level by the next morning. No headache, light sensitivity or visual aura came with it. He has had dull headaches on two other days, without dizziness. His mood is still low; he is sleeping five or six hours, feels guilty and joyless, and has had to push himself to write and teach. He has had no thoughts of death or of harming himself. He has never had a period of days with little need for sleep, racing thoughts or unusual energy. [S]
| Element | Detail |
|---|---|
| Attacks | One since intake, three hours, with left-ear roaring and fullness |
| Meclizine | One dose |
| Headache | Two dull headaches without dizziness; none with the attack |
| Mood | Low, guilty, joyless; poor sleep; no thoughts of self-harm |
| Mania screen | No past hypomanic or manic episodes |
| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Positive | Constant left-ear tinnitus and fullness; muffled hearing on the left |
| Neurological | Positive | One vertigo attack; two dull headaches; no weakness, numbness, double vision or slurred speech |
| Gastrointestinal | Positive | Nausea during the attack; bowels regular |
| Genitourinary | Negative | No flank pain or blood in the urine |
| Psychiatric | Positive | Low mood, guilt, loss of interest, broken sleep; no suicidal ideation |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Meclizine 25 mg tablet, one by mouth up to every 8 hours during a severe vertigo attack only, for no more than 3 days at a time | every 8 hours as needed during a severe attack, at most 3 days at a time | Oral route | 2026-07-28 | active | S |
| Hydrochlorothiazide 25 mg tablet, one by mouth each morning | once daily in the morning | Oral route | 2026-08-11 | active | S |
| Sertraline 25 mg tablet, one by mouth each morning for one week | once daily in the morning | Oral route | 2026-08-11 to 2026-08-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-11 | Body height | 175 | cm | S |
| 2026-08-11 | Body weight | 86.2 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 74 | /min | S |
| 2026-08-11 | Respiratory rate | 14 | /min | S |
| 2026-08-11 | Body temperature | 36.6 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S |
Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well-built man; blood pressure 126/80, pulse 74; weight 86.2 kg |
| Ears | Ear canals and tympanic membranes normal; Weber lateralizes to the right; Rinne positive on both sides |
| Neurological | No spontaneous or gaze-evoked nystagmus; head impulse test normal; cranial nerves, coordination and gait normal; Romberg steady |
| Psychiatric | Mood low, affect constricted; speech fluent and forceful; no suicidal ideation; no psychotic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent attacks of spinning vertigo for about three months, the worst twelve days ago, lasting hours, with roaring tinnitus, fullness and muffled hearing in the left ear and nausea, the tinnitus persisting between attacks; with low mood, poor sleep and loss of interest; cause not established at intake: an inner-ear disorder suspected, with vestibular migraine, vestibular schwannoma and posterior circulation stroke to be excluded and depression to be assessed; otology consultation requested | resolved | confirmed | R42 | S — Synthetic presenting problem anchored to his documented attacks of April and July 1527; superseded by the diagnoses at the second visit. |
| Ménière disease of the left ear, definite (AAO-HNS 2020 and Bárány Society criteria), with low-frequency sensorineural hearing loss and persistent tinnitus in the left ear; vestibular migraine considered and judged unlikely as the main cause; vestibular schwannoma excluded by MRI | active | confirmed | H81.02 | S — Synthetic modern diagnosis made at the otology consultation, linked to his documented attacks and to the retrospective diagnosis of Ménière disease (R). |
| Major depressive disorder, recurrent, moderate (DSM-5-TR), with low mood, poor sleep, loss of interest, guilt and fatigue for about two months, after earlier periods of spiritual crisis and low mood; no suicidal ideation | active | confirmed | F33.1 | S — Synthetic modern diagnosis linked to his documented Anfechtungen and low periods; not a claim that he was so diagnosed; the retrospective psychiatric readings are disputed (R). |
| Urinary stone disease: one stone passed spontaneously last year after severe pain; stone type and metabolic risk not yet known at intake | active | confirmed | Z87.442 | S — Synthetic modern problem anchored to his documented first stone in 1526. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Vertigo attack diary: number, duration, hearing, tinnitus, fullness, headache | Every visit | Completed today | One three-hour attack since intake; two headaches without vertigo; Dizziness Handicap Inventory 52 (moderate) (Dizziness Handicap Inventory in the notes; no LOINC code used) |
| Examination | Audiometry (pure-tone and speech) with tympanometry | At diagnosis; repeat at about three months and with any change in hearing | Completed today | Left low-frequency sensorineural loss of 40 dB at 250 and 500 Hz; word recognition 88 percent left, 100 percent right; normal tympanograms |
| Imaging | MRI of the internal auditory canals with gadolinium | Once, to exclude a retrocochlear lesion with asymmetric hearing loss | Ordered | Ordered today |
| Examination | Vestibular function testing and electrocochleography | Not routinely for diagnosis | Not indicated | The guideline advises against routine testing to diagnose Ménière disease; the history and audiogram are enough |
| Medication safety | Vestibular suppressant use | Every visit | Completed today | One meclizine dose in two weeks; limited to severe attacks |
| Self-management | Sodium, caffeine and alcohol limits | Every visit | Ordered | Education given today |
| Referral | Otology consultation | Once, at diagnosis | Completed today | Seen by Dr. Okafor-Lindqvist today |
| Survey | PHQ-9 | At least monthly during acute treatment | Completed today | 14, from 15 at intake |
| Survey | Mood Disorder Questionnaire at the initial depression workup | Once at the initial workup; repeat if hypomanic features emerge | Completed today | Negative; no past hypomania or mania |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit | Completed today | No suicidal ideation, intent or plan; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Ordered | Due in two weeks; with the sodium check on the thiazide |
| Laboratory | Sodium, potassium, creatinine and calcium on a thiazide with an SSRI | Two to four weeks after starting, then every three to six months | Ordered | Sodium and potassium in two to four weeks |
Goal progress:
Guideline basis: Clinical Practice Guideline: Ménière's Disease (2020); Diagnostic criteria for Menière's disease (2015); Vestibular migraine: diagnostic criteria (update) (2022); Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) (2016); Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Blood test in two to four weeks. Review in six weeks. Next scheduled visit 2026-09-08: periodic adult preventive visit. [S]